{"id":"https://openalex.org/W2559890484","doi":"https://doi.org/10.1016/s0959-8049(16)32607-7","title":"Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers","display_name":"Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers","publication_year":2016,"publication_date":"2016-12-01","ids":{"openalex":"https://openalex.org/W2559890484","doi":"https://doi.org/10.1016/s0959-8049(16)32607-7","mag":"2559890484"},"language":"en","primary_location":{"id":"doi:10.1016/s0959-8049(16)32607-7","doi":"https://doi.org/10.1016/s0959-8049(16)32607-7","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0959-8049(16)32607-7","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068368047","display_name":"Timothy Anthony Yap","orcid":"https://orcid.org/0000-0002-2154-3309","observed_orcids":["https://orcid.org/0000-0002-2154-3309"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T.A. Yap","raw_affiliation_strings":["FBMH Faculty Office Administration (L5)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"FBMH Faculty Office Administration (L5)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080991347","display_name":"Matthew Krebs","orcid":"https://orcid.org/0000-0001-7540-3064","observed_orcids":["https://orcid.org/0000-0001-7540-3064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M.G. Krebs","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008444865","display_name":"Sophie C. Postel-Vinay","orcid":"https://orcid.org/0000-0001-5562-1857","observed_orcids":["https://orcid.org/0000-0001-5562-1857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Postel-Vinay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050684671","display_name":"Yung\u2010Jue Bang","orcid":"https://orcid.org/0000-0001-6000-4597","observed_orcids":["https://orcid.org/0000-0001-6000-4597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y.J. Bang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079196729","display_name":"A.B. El-Khoueiry","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. El-Khoueiry","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062426672","display_name":"Wassim M. Abida","orcid":"https://orcid.org/0000-0002-9006-7043","observed_orcids":["https://orcid.org/0000-0002-9006-7043"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Abida","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072284989","display_name":"Kevin Joseph Harrington","orcid":"https://orcid.org/0000-0002-6014-348X","observed_orcids":["https://orcid.org/0000-0002-6014-348X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Harrington","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053619368","display_name":"Raghav Sundar","orcid":"https://orcid.org/0000-0001-9423-1368","observed_orcids":["https://orcid.org/0000-0001-9423-1368"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Sundar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033090749","display_name":"Louise Carter","orcid":"https://orcid.org/0000-0002-9854-2304","observed_orcids":["https://orcid.org/0000-0002-9854-2304"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Carter","raw_affiliation_strings":["FBMH Faculty Office Administration (L5)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"FBMH Faculty Office Administration (L5)","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114092866","display_name":"Eduardo Casta\u00f1\u00f3n \u00c1lvarez","orcid":"https://orcid.org/0000-0003-2957-4414","observed_orcids":["https://orcid.org/0000-0003-2957-4414"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Castanon-Alvarez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069050806","display_name":"Seock\u2010Ah Im","orcid":"https://orcid.org/0000-0002-5396-6533","observed_orcids":["https://orcid.org/0000-0002-5396-6533"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S.A. Im","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111468461","display_name":"Ali\u00e9nor Berges","orcid":"https://orcid.org/0000-0002-7078-327X","observed_orcids":["https://orcid.org/0000-0002-7078-327X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Berges","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009280195","display_name":"Maryam I. Khan","orcid":"https://orcid.org/0000-0002-8454-0201","observed_orcids":["https://orcid.org/0000-0002-8454-0201"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Khan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008492137","display_name":"Christina Alexandra Stephens","orcid":"https://orcid.org/0000-0001-9382-003X","observed_orcids":["https://orcid.org/0000-0001-9382-003X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Stephens","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"G. Ross","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Ross","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021624793","display_name":"Jean\u2010Charles Soria","orcid":"https://orcid.org/0000-0001-9597-0701","observed_orcids":["https://orcid.org/0000-0001-9597-0701"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J.C. Soria","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":null,"fwci":1.8708,"has_fulltext":false,"cited_by_count":48,"citation_normalized_percentile":{"value":0.87456078,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"69","issue":null,"first_page":"S2","last_page":"S2"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/azd6738","display_name":"AZD6738","score":0.9959999918937683},{"id":"https://openalex.org/keywords/atr-inhibitors","display_name":"ATR inhibitors","score":0.9150000214576721},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9589999914169312},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":1.0},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":1.0},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7900000214576721},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.7239999771118164},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7860000133514404},{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.49000000953674316},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.42899999022483826}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.9401634931564331},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.7310049533843994},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6386103630065918},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5674694776535034},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.4742911458015442},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.454440712928772},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3804379105567932},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3270530104637146},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29189109802246094},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.15280234813690186},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.1440715491771698},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1395941972732544},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.10902741551399231},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.10763615369796753},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.09027090668678284},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s0959-8049(16)32607-7","doi":"https://doi.org/10.1016/s0959-8049(16)32607-7","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0959-8049(16)32607-7","pdf_url":null,"source":{"id":"https://openalex.org/S16731738","display_name":"European Journal of Cancer","issn_l":"0959-8049","issn":["0959-8049","1879-0852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Cancer","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2886880700","https://openalex.org/W2896523388","https://openalex.org/W2805040559","https://openalex.org/W2786524841","https://openalex.org/W2983091979","https://openalex.org/W2742085535","https://openalex.org/W3029290509","https://openalex.org/W4210508140","https://openalex.org/W2978929492","https://openalex.org/W2507224706"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-12-16T00:00:00"}